US Patent

US9382217 — Modulators of sphingosine phosphate receptors

Method of Use · Assigned to Scripps Research Institute · Expires 2029-05-14 · 3y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects compounds that activate a specific type of receptor in the body, known as the S1P1 receptor subtype, for medical treatment.

USPTO Abstract

Compounds that activate a sphingosine-1-phosphate receptor of the subtype 1 are provided. Certain compounds selectively activate the receptor subtype 1 in relation to the sphinogosine-1-phosphate receptor subtype 3. Uses and methods of inventive compounds for treatment of malconditions wherein activation, agonism, inhibition or antagonism of the S1P1 is medically indicated are provided.

Drugs covered by this patent

ozanimod-hydrochloride (OZANIMOD HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2774`	—	ozanimod-hydrochloride
`U-2774`	—	ozanimod-hydrochloride
`U-2774`	—	ozanimod-hydrochloride

Patent Metadata

Patent number: US9382217
Jurisdiction: US
Classification: Method of Use
Expires: 2029-05-14
Drug substance claim: No
Drug product claim: No
Assignee: Scripps Research Institute
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.